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Abstract
Objective—Protease-activated receptor-2 (PAR-2) signaling enhances inflammation in different
diseases. The effect of PAR-2 deficiency in cardiac ischemia/reperfusion (I/R) injury is unknown.
We investigated the effect of PAR-2 deficiency on I/R injury-induced infarct size, inflammation,
heart remodeling and cardiac function.
Methods and Results—PAR-−/−- mice and wild-type (WT) littermates were subjected to 30
minutes of ischemia and up to 4 weeks of reperfusion. Infarct size, oxidative/nitrative stress,
phosphorylation of mitogen-activated protein kinases (MAPK) and inflammatory gene expression
were assessed 2 hours after reperfusion. Changes in heart size and function were measured by
echocardiography up to 4 weeks after reperfusion. Infarct size was significantly reduced in hearts of
PAR-2−/− mice compared to WT littermates. In addition, oxidative/nitrative stress, phosphorylation
of MAPK and expression of pro-inflammatory genes were significantly attenuated in injured hearts
of PAR-2−/− mice. Finally, PAR-2−/− mice were protected from post-infarction remodeling and
showed less impairment in heart function compared with WT littermates up to 4 weeks after I/R
injury.
Conclusion—PAR-2 deficiency reduces myocardial infarction and heart remodeling following I/
R injury.
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Protease-activated receptors (PARs) are a family of seven transmembrane domain G protein–
coupled receptors activated by proteolytic cleavage1. The PAR family consists of four
members: PAR-1 to -4. PAR-2 is activated by several proteases, including trypsin, mast cell
tryptase, matriptase and the coagulation proteases factor VIIa (FVIIa) and FXa1–4. PAR-2 can
be also activated by synthetic agonist peptides corresponding to the tethered ligand
sequence1. Activation of PAR-2 leads to an elevation of intracellular Ca2+ and stimulation of
multiple intracellular signaling pathways, including MAPK pathways1, 5, 6.
PAR-2-dependent signaling has been shown to play an important role in many animal models
of inflammatory diseases. Recent studies demonstrated a role of PAR-2 in leukocytes rolling,
arthritis, inflammatory pain and allergic inflammation, as well as in skin disorders7–12. In
contrast, other studies support a protective role of PAR-2 in airway inflammation, ischemic
brain injury, and influenza virus infection13–15. Furthermore, in a mouse model of Alzheimer’s
disease, PAR-2 protects neurons from beta-amyloid induced toxicity, but its activation in
microglia cells led to neurotoxicity16. These studies indicate that PAR-2 activation on different
cell types may have detrimental or protective effects in different disease models.
Myocardial infarction (MI) is one of the leading causes of mortality and morbidity in the
Western world17. Coronary vessel occlusion and subsequent ischemia results in myocardial
cell death18. Early restoration of blood flow within the coronary vessels is necessary to provide
oxygen and nutrients to the ischemic area. However, reperfusion itself contributes to injury of
the heart by initiating a local inflammatory response, which leads to further myocardial
damage17, 18. This is known as ischemia/reperfusion (I/R) injury. With time, areas of the
initial infarct are replaced by collagen-rich scar tissue. The acute loss of myocardial cells results
in abnormal loading conditions that involve not only the border zone of infarction, but also the
remote myocardium. These abnormal loading conditions lead to hypertrophy, aberrant cardiac
remodeling, and ultimately heart failure17, 18.
PAR-2 is express by numerous cell types within the cardiovascular system. Functional PAR-2
expression has been demonstrated on vascular endothelium, smooth muscle cells and
cardiomyocytes but not on cardiac fibroblasts5, 6. In addition, PAR-2 is expressed on activated
neutrophils19. In vitro studies demonstrated that PAR-2 activation on cultured cardiomyocytes
results in a series of molecular and morphological changes that lead to hypertrophic growth6.
Furthermore, several recent papers reported that activation of PAR-2 with a PAR-2 agonist
peptide has a beneficial effect in both ex vivo and in vivo models of cardiac I/R injury20–22.
The protective mechanism involved vasodilation of coronary vessels, which was mediated by
activation of PAR-2 on endothelial cells21. However, the effect of global deficiency of PAR-2
on myocardial infarction has not been investigated.
In this study, we investigated the role of PAR-2 in cardiac I/R injury. We found that PAR-2
deficiency resulted in a significant reduction in inflammation and infarct size, as well as
attenuation of pathologic heart remodeling.
Methods
Human study
PAR-1 and PAR-2 mRNA levels were determined in heart samples from the LV (LV) free wall
(toward the apex) of 5 male patients in end-stage HF of ischemic origin (mean age 57+/−9) at
the time of left ventricular assist device placement. Non-failing tissue was obtained from the
LV free wall (toward the apex) of five male non-failing organ donor hearts rejected for
transplant for physical incompatibilities (mean age 48+/−7). LV tissue obtained from surgery
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was immediately frozen in liquid nitrogen and stored at −80°C. All surgical procedures and
tissue harvesting were performed with informed patient consent and are concordant with NIH
and University of Rochester Institutional Review Board guidelines.
Mice
PAR-2+/− mice were backcrossed onto a C57Bl/6J background and intercrossed to generate
PAR-2−/− and wild-type (WT) littermate mice23. Male mice (8–12 weeks of age) were used
for experiments. All experiments were approved by the Animal Care and Use Committees of
the different institutions and complied with National Institute of Health guidelines.
Cardiac I/R injury model
For the short-term I/R model (30 minutes of ischemia and 2 hours of reperfusion), the surgical
protocol and infarct-size determination were performed as previously described24 with some
modifications. Briefly, intraperitoneal injection of pentobarbital (100 mg/kg; Abbott
Laboratories, Abbott Park, IL) was used for anesthesia. Mice were intubated orally to provide
artificial ventilation (0.3 mL tidal volume, 120 breaths/min). The left anterior descending
coronary artery was occluded with a 7-0 silk suture (US Surgical Corp, Norwalk, Conn) passed
through PE tubing (US Surgical Corp) to make a Rumel snare. After 30 minutes of ischemia,
the snare was released, and the heart was reperfused for 2 hours. Finally, the artery was
reoccluded, and 4% Evans Blue dye was injected into the aortic root to delineate the area at
risk from not-at-risk myocardium (blue). Hearts were then explanted, rinsed in 0.9% normal
saline, and placed in 1% agarose gel (UltraPure agarose, Life Technologies, Gaithersburg, MD)
in PBS (pH 7.4). Hearts were sectioned parallel to the AV groove in ≈1-mm sections. Viable
and necrotic sections of the area at risk were identified by incubating the hearts in 1% 2,3,5-
triphenyltetrazolium chloride (Sigma-Aldrich, St Louis, Mo) for 10 minutes at 37°C followed
by 10% neutral buffered formaldehyde for 24 hours. Each section was weighed and
photographed. The LV, area at risk, and infarct areas were traced and calculated by computer
planimetry (Image J, version 1.21). Infarct volumes were calculated as [(A1xW1)+(A2xW2)+
(A3xW3)+(A4xW4)+(A5xW5)], where A is the area of infarct for the slice denoted by the
subscript and W is the weight of the respective section.
The long-term model (30 minutes of ischemia and 4 weeks of reperfusion) was performed in
a similar manner. Ischemia was validated via ECG recordings. After 30 minutes of ischemia,
occlusion of the left anterior descending coronary artery was released, the wound was closed
and animals were returned to their cages. Surgery was performed in a blinded fashion.
TaqMan® Real-time Polymerase Chain Reaction (PCR)
Total RNA was isolated using Trizol reagent and reverse transcribed into cDNA using
RETROscript® Kit (Applied Biosystems, Foster City, California). Levels of different mRNAs
were analyzed by real-time PCR using RealMasterMix and realplex2 Mastercycler (Eppendorf
AG, Hamburg, Germany). TaqMan primer and probe sets (Applied Biosystems) were used to
analyze the mRNA expression of: mouse IL-1β (Mm01336189_m1), mouse IL-6
(Mm99999064_m1), mouse TNF-α (Mm00443259_g1), mouse KC (Mm00433859_m1),
mouse MCP-1 (Mm00441242_m1), mouse MIP-2 (Mm00436450_m1), mouse PAR-1
(Mm00438851_m1), mouse PAR-2 (Mm00433160_m1), human PAR-1 (Hs00169258-m1)
and human PAR-2 (Hs00608346-m1). The mRNA expression of glyceraldehyde-3-phosphate
dehydrogenase (4352339E) was used as internal control.
ELISA
Protein extracts were generated from mouse hearts as previously described25. Cytokine and
chemokine protein expression in the hearts was analyzed by Quantikine ELISAs (R&D
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Systems, Minneapolis, MN, USA). Levels of 3-nitrotyrosine, a marker of oxidative/nitrative
stress, was analyzed using commercial elisa assay (Hbt Hycult Biotechnology, Uden, The
Netherlands). Phosphorylation of the MAP kinases ERK1/2, JNK and p38 as well as AKT was
analyzed in heart lysates with the Duo-Set IC Kit (R&D Systems). All ELISAs were performed
according to the manufactures’ instructions. Data were normalized to the protein concentration
in respective lysates and compared to non-injured WT hearts. Protein concentration was
measured using Bio Rad Dc Protein Assay (Bio-Rad Laboratories, Hercules, CA).
Echocardiography
Echocardiography was performed using a VisualSonics Vevo 660 ultrasound system as
described24. Diameter of LV and LV wall thickness at the end of systole and diastole were
measured digitally on M-mode tracings and averaged from 4 cardiac cycles. Fractional
shortening (FS) was then calculated from measured ventricle dimensions.
Heart weight to body weight ratio
Hearts were stopped at diastole by intra-ventricular injection of 1mL 20mM KCl solution.
Heart weight to body weight ratio (HW:BW) was calculated by dividing the HW (mg) by BW
(g).
Histology
Hearts were fixed with 10% formalin solution and embedded in paraffin. Deparaffined sections
were stained with the Masson’s trichrome.
Statistic analysis
All statistical analyses were performed using GraphPad Prism version 5.01. Data are
represented as means ± SEM. For two group comparison of parametric data, a Student’s t-test
was performed. For multiple group comparison, one-way ANOVA or two-way ANOVA tests
were performed followed by Bonferroni post test analysis.
Results
MI upregulates PAR-1 and PAR-2 expression
We used short-term (30 minutes ischemia and 2 hours of reperfusion) and long-term (30
minutes ischemia and 4 weeks of reperfusion) mouse models of I/R injury to determine if the
expression levels of PAR-1 and PAR-2 mRNA are altered during MI and heart remodeling,
respectively. We found that levels of PAR-2 but not PAR-1 mRNA expression were
upregulated in injured hearts 2 hours after reperfusion (Figure 1A and B). In the long-term
model, we observed a significant increase in both PAR-1 and PAR-2 mRNA expression in the
hearts (Figure 1A and B).
Next, we analyzed the levels of PAR-1 and PAR-2 mRNA expression in heart biopsies obtained
from patients with ischemic heart failure. PAR-1 and PAR-2 mRNA expression were
significantly upregulated in failing hearts compared to the levels observed in the biopsies from
healthy donors (Figure 1C and D).
PAR-2 deficiency reduces infarct size
To investigate the role of PAR-2 deficiency in MI, PAR-2−/− and WT littermate mice were
subjected to 30 minutes of ischemia and 2 hours of reperfusion. We found that infarct size was
significantly reduced in hearts of PAR-2−/− mice compared to WT littermates (24.3±1.7% vs.
35.8±3.4%) with no significant changes in the area at risk (Figure 2A).
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Oxidative/nitrative stress is attenuated in the injured hearts of PAR-2−/− mice
It has been demonstrated that formation of peroxynitrite (ONOO−), a product of nitric oxide
and superoxide interaction, contributes to the MI by inducing oxidative /nitrative stress26–28.
Nitrotyrosine is a stable end product of peroxynitrite oxidation and has been used as a marker
of oxidative/nitrative stress in a mouse model of cardiac I/R injury26–28. After 30 minutes of
ischemia and 2 hours of reperfusion, the level of nitrotyrosine in myocardial tissue was
significantly increased in the hearts of WT mice (Figure 2B). Importantly, the level of
nitrotyrosine in injured hearts of PAR-2−/− mice was significantly reduced compared to the
level observed in injured hearts of WT mice (Figure 2B).
PAR-2 deficiency reduces activation of MAPK pathways
It has been demonstrated that activation of various MAPK pathways contributes to
inflammation in the setting of I/R injury29, 30. PAR-2 deficiency had no effect on basal
phosphorylation levels of ERK-1/2, p38 and JNK in mouse hearts. I/R injury (30 minutes of
ischemia and 2 hours of reperfusion) resulted in increased phosphorylation of all three MAPKs
in the hearts of WT mice (Figure 3A–C). Importantly, activation of ERK-1/2, p38 and JNK
was significantly attenuated in the hearts of PAR-2−/− mice (Figure 3A–C). In contrast, PAR-2
deficiency had no effect on phosphorylation of AKT (Figure 3D).
PAR-2 deficiency attenuates inflammatory gene expression in the heart
Cardiac I/R injury induced the expression of a variety of inflammatory mediators, including
IL-1β, IL-6, TNF-α and KC 2 hours after reperfusion at both mRNA and protein levels (Figure
4A and B). Importantly, injured hearts of PAR-2−/− mice exhibited significantly less IL-1β,
TNF-α and KC mRNA expression compared with injured hearts of WT mice (Figure 4A). The
IL-6 mRNA expression was also attenuated in PAR-2−/− mice but did not reach statistical
significance (Figure 4A). Consistent with changes of mRNA expression, protein levels of
IL-1β, IL-6, TNF-α and KC were significantly reduced in the injured hearts of PAR-2−/− mice
compared with injured hearts of WT mice (Figure 4B). PAR-2 deficiency did not effect
expression of MCP-1 and MIP-2 in injured hearts (data not shown).
PAR-2 deficiency reduces cardiac remodeling and heart dysfunction
To study the role of PAR-2 in heart remodeling, PAR-2−/− and WT littermate mice were
subjected to 30 minutes of ischemia followed by 4 weeks of reperfusion period. Gross
morphological analysis of heart cross-sections demonstrated that injured hearts of WT mice
were larger with visible dilatation of the LV compared to injured hearts of PAR-2−/− mice
(Figure 5A). I/R injury resulted in a significant increase in the HW:BW ratio in WT mice
indicating hypertrophic remodeling of the hearts (Figure 5B). Importantly, the increase in
HW:BW ratio was significantly smaller in PAR-2−/− mice compared with WT littermates
(Figure 5B).
To analyze the heart function, echocardiography was performed before and up to 4 weeks after
cardiac I/R injury in PAR-2−/− and WT littermate mice. Before surgery, the morphological and
functional parameters of hearts were similar between WT and PAR-2−/− mice (day 0) (Figure
6). After cardiac I/R injury, PAR-2−/− mice showed significantly less ventricular dilatation
compared to WT littermates, as demonstrated by changes in LV diameter and volume at the
end of systole (Figure 6A and B). Moreover, 3 weeks after the I/R injury, thinning of the LV
posterior wall was significantly attenuated in the heart of PAR-2−/− mice at the end of systole
compared to WT mice (Figure 6C). I/R injury or PAR-2 deficiency had no effect on these three
parameters at the end of diastole (data not shown). Importantly, PAR-2−/− mice showed
significantly less impairment in the heart function after cardiac I/R injury, measured by
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percentage of fractional shortening (Figure 6D). These data indicate that PAR-2 deficiency
protects against systolic heart dysfunction induced by I/R injury.
Discussion
In this study, we found that PAR-2 deficiency reduces MI in a mouse model of cardiac I/R
injury. Interaction between nitric oxide and superoxide anion, one of the reactive oxygen
species (ROS) generated during cardiac I/R injury, results in the formation of highly cytotoxic
molecule peroxynitrite31. Peroxynitrite mediated toxicity involves direct oxidative damage to
lipids, proteins and DNA, the activation of metalloproteinases, the impairment of
mitochondrial respiration, and the nitration of tyrosine residues within proteins32. The
reduction of nitrotyrosine levels in the myocardium of PAR-2 deficient mice suggests that
oxidative/nitrative stress is one of the mechanisms by which PAR-2 may enhances MI. This
concept is supported by recent publications indicating that activation of PAR-2 leads to
generation of both nitric oxide and ROS, including superoxide anion19, 33, 34.
During I/R injury, release of ROS results in the activation of MAPKs35. Furthermore, activation
of PAR-2 also leads to phosphorylation of MAPKs in various cell types, including
cardiomyocytes and endothelial cells6, 36. Recent studies demonstrated that activation of
MAPKs enhance inflammation and contribute to MI. For example, overexpression of a
dominant-negative p38 MAPK or inhibition of JNK MAPK results in significant protection
from I/R injury30, 37. Moreover, reduced activation of MAPK was correlated with smaller
infarcts in mice deficient for the lectin-like receptor for oxidize-LDL38. In our study, we
demonstrated that the smaller infarcts observed in the hearts of PAR-2−/− mice after I/R injury
was associated with reduced phosphorylation of ERK-1/2, p38 and JNK and attenuated
expression of various inflammatory mediators. Therefore, we propose that PAR-2 contributes
to MI, in part, by enhancing inflammation in a MAPK-dependent manner.
Many cell types can contribute to a PAR-2-mediated inflammatory response within injured
myocardium. One of them is endothelial cells. It has been demonstrated that activation of
PAR-2 on endothelial cells induces the expression of IL-1β, IL-6 and IL-8 (human homolog
of mouse KC)39, 40. The production of chemokines leads to the recruitment of leukocytes,
including neutrophils and monocytes, into the injured myocardium41. Both cell types have
been shown to express PAR-219, 42. It has been shown that PAR-2 signaling plays a role in
leukocyte adhesion, rolling and migration7, 43. Furthermore, monocytes/macrophages and
neutrophils expresses multiple inflammatory cytokines, and may be a source of TNF-α and
IL-1β in the injured myocardium42, 44–46. Therefore, PAR-2-dependent signaling in
endothelial cells and leukocytes will increase the expression of inflammatory mediators.
There is a growing body of evidence that, in addition to endothelial cells and leukocytes,
cardiomyocytes can also contribute to the expression of inflammatory mediators. Activation
of Toll-like receptors (TLRs) in cardiomyocytes, including TLR-4, leads to the expression of
IL-6, KC and MIP-247. Importantly, TLR4 signaling has been shown to play a role in MI and
inflammation after I/R injury48. Our preliminary data indicate that activation of PAR-2 in
cultured neonatal mouse cardiomyocytes also results in the expression of IL-6 and KC but not
TNFα or MIP-2 protein (S. Antoniak, N. Mackman and R. Pawlinski - unpublished data).
Therefore, during I/R injury, activation of PAR-2 on cardiomyocytes may contribute to the
expression of IL-6 and KC. Interestingly, it has been demonstrated that PAR-2-mediated
expression of IL-1β was significantly attenuated in TLR4 deficient macrophages49.
Furthermore, the TLR/IL-1 receptor-like domain of TLR4 has been found to interact with the
cytoplasmic C-terminus of PAR-250. A mutation of this domain abolished PAR-2 dependent
activation of NF-κB in macrophages50. Further studies are required to determine if TLR4 and
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PAR-2 cooperate in a similar manner in cell types within the injured heart to enhance
inflammation.
We also demonstrated that PAR-2 deficiency reduced heart remodeling and heart dysfunction
up to 4 weeks after injury. This is may be due to a smaller initial infarct size in the hearts of
PAR-2−/− mice. It is known that the size of the initial infarct affects the extent of heart
remodeling after MI17, 18. In addition, activation of PAR-2 has been shown to induce
hypertrophic growth of cardiomyocytes in vitro6. Since hypertrophic growth is a major
component of post-MI remodeling, it is possible that PAR-2 may also contribute to heart
remodeling by increasing the hypertrophic growth of cardiomyocytes.
In contrast to the reduced infarct size observed in PAR-2−/− mice, we have previously
demonstrated that deficiency of PAR-1 has no effect on infarct size in the same short-term
model of cardiac I/R injury24. This indicates that there are differences between PAR-1 and
PAR-2 dependent signaling in MI. In the present study, we showed that short-term cardiac I/
R injury led to the significant increase of PAR-2 but not PAR-1 mRNA expression. This may
explain, in part, the different effects of PAR-1 and PAR-2 deficiency on MI. Inducible
expression of PAR-2 is likely to play pathologic role in the inflammatory response during I/R
injury. We also showed that PAR-1 and PAR-2 mRNA expression in the heart is significantly
increased in long-term model of I/R injury, as well as in heart samples from patients who
developed ischemic heart failure. It is uncertain if the increased expression of these two genes
contributes to the development of heart failure or is just an effect of heart remodeling. Our
previous data indicate that increase PAR-1 signaling in cardiomyocytes leads to the
development of eccentric heart hypertrophy and reduction of heart function24. We also found
that cardiomyocyte-specific overexpression of PAR-2 led to heart hypertrophy (S. Antoniak,
N. Mackman and R. Pawlinski – unpublished data). These data, together with the observation
that not only PAR-2 deficiency, but also PAR-1 deficiency significantly reduced long-term
heart remodeling24, suggest that both PAR-1 and PAR-2 may contribute to ischemic heart
failure in humans.
Our study raises the question of what protease(s) activate PAR-2 during cardiac I/R injury. We
and others have previously demonstrated that tissue factor (TF), the primary initiator of
coagulation cascade, contributes to MI in rabbit and mouse models of cardiac I/R injury51–
53. Subsequently, it has been shown that TF-dependent thrombin generation and fibrin
deposition enhances MI24, 54. Importantly, the TF:FVIIa complex can activate PAR-2, which
is one possible mechanism of PAR-2 activation during I/R injury2, 3. Further studies are
required to determine if TF:FVIIa and/or FXa activate PAR-2 in injured hearts. In addition,
PAR-2 can be activated by other proteases, such as mast cell tryptase5. Mast cells have been
found between muscle fibers in the heart and mast cell deficient mice exhibit reduced infarct
size and inflammation after cardiac I/R injury55, 56. This may be due, in part, to a reduction in
PAR-2 activation.
In contrast to our results, several recent publications have reported that activation of PAR-2
with a synthetic PAR-2 agonist peptide has a beneficial effect in both ex vivo and in vivo rat
models of cardiac I/R injury20–22. How can administration of PAR-2 agonist peptide be
protective whereas a global deficiency of PAR-2 results in a smaller infarct? It has been
demonstrated that depending on the disease model activation of PAR-2 may have either
protective or detrimental effects. Furthermore, recent studies in mouse model of Alzheimer’s
disease suggest that PAR-2-dependent signaling may have opposite effects in different cell
types within the brain16. It is possible that a similar scenario may occur in the heart after I/R
injury. In the short-term I/R injury model activation of PAR-2 on endothelial cells may be
protective, whereas PAR-2 signaling on other cell types, like cardiomyocytes or infiltrating
leukocytes may lead to the detrimental effects. Another possible explanation for these different
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results came from a recent paper demonstrating that PAR-2 is differentially activated by
tethered ligands versus soluble ligands, such as an agonist peptide57. These two types of ligands
differentially bind and stabilized different conformations of the receptor resulting in activation
of distinct subsets of signaling cascades57. A better understanding of the cell type-specific
responses of PAR-2 during cardiac I/R injury is needed. Interestingly, PAR-2 deficiency and
treatment with PAR-2 agonist peptide had beneficial effects not only in heart I/R injury but
also in the mouse model of colitis induced by intrarectal injection of trinitrobenzene sulfonic
acid58, 59.
In summary, we demonstrated that PAR-2 deficiency reduces inflammation, myocardial
infarction and cardiac remodeling after I/R injury. Further studies are required to determine
the effect of inhibition of PAR-2 in WT mice before considering PAR-2 as a potential target
for therapy to prevent myocardial damage.
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Figure 1. PAR-1 and PAR-2 mRNA expression in injured mice and humans hearts
Murine PAR-1 (A) and PAR-2 (B) mRNA expression was analyzed using real-time PCR in
C57BL/6 WT mice hearts before (n=8) and after 30 minutes of ischemia and 2 hours (n=5) or
4 weeks (n=7) of reperfusion. Human PAR-1 (C) and PAR-2 (D) mRNA expression was
analyzed by real-time PCR in human heart samples from patients with ischemic HF (n=5) and
compared to mRNA expression in healthy controls n=5). * P<0.05 vs. un-injured or healthy
controls
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Figure 2. PAR-2 deficiency reduces myocardial infarction and oxidative/nitrative stress after short
term I/R injury
A: Area at the risk (AAR), determined as a percentage of LV area and infarct size, determined
as a percentage of AAR in WT (white bars, n=7) and PAR-2−/− (black bars, n=13) mice
subjected to 30 minutes of ischemia and 2 hours of reperfusion. * P<0.05 vs. injured WT mice.
B: Levels of 3-nitrotyrosine in heart lysates of control mice (n=4 for WT and PAR-2−/−) and
mice subjected to 30 minutes of ischemia and 2 hours of reperfusion (n=8 for WT (white bars)
and n=8 for PAR-2−/− (black bars)). * P<0.05 vs. pre-I/R injury group within the same
genotype.
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Figure 3. PAR-2 deficiency results in reduced intracellular signaling in heart after I/R injury
Activation of MAPK (A: ERK1/2; B: p38; C: JNK) and AKT (D) were analyzed in heart
lysates of control mice (n=4 for WT and PAR-2−/−) and mice subjected to 30 minutes of
ischemia and 2 hours of reperfusion (n=8 for WT (white bars) and n=8 for PAR-2−/− (black
bars)). The phosphorylation state of the non-injured WT littermates was set to 100%. * P<0.05
vs. pre-I/R injury group within the same genotype.
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Figure 4. PAR-2 deficiency reduces myocardial inflammation after I/R injury
A: Levels of pro-inflammatory cytokine and chemokine mRNAs in the hearts of control mice
(n=4 for WT and PAR-2−/−) and mice subjected to 30 minutes of ischemia and 2 hours of
reperfusion (n=10 for WT (white bars) and n=8 for PAR-2−/− (black bars)). mRNA expression
in the injured WT hearts were set to 1. B: Protein levels of inflammatory mediators IL-1β,
IL-6, TNF-α and KC in hearts before and after short-term I/R injury (n=8 for WT and n=8 for
PAR-2−/−). * P<0.05 vs. pre-I/R injury group within the same genotype.
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Figure 5. Effects of a PAR-2 deficiency on heart remodeling 4 weeks after cardiac I/R injury
A: Representative cross-sections from WT and PAR-2−/− hearts 4 weeks after cardiac I/R injury
cut at the level of papillary muscles and stained with Masson’s Trichrome. The scar tissue is
stained blue. B: HW:BW ratio of non-injured controls (n=4 each group) and injured WT (white
bars, n=7) and PAR-2−/− (black bars, n=6) mice. * P<0.05 vs. pre-I/R injury group within the
same genotype.
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Figure 6. Echocardiographic analysis of heart size and function
A: Systolic left ventricular internal diameter (LVID s), B: systolic left ventricular volume (LV
Vols), C: thickness of LV posterior wall at the end of systole (LVPW) and D: Percentage of
fractional shortening (FS) was analyzed by echocardiography before and up to 4 weeks after
cardiac I/R injury in WT (n=7) and PAR-2−/− (n=6) mice. * P<0.05 vs. pre-I/R injury group
within the same genotype.
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